Floatz logo

Midostaurin

Systemic Mastocytosis With An Associated Clonal Hematologic Non-Mast Cell Lineage Disease

Jason Robert GotlibSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Systemic Mastocytosis With An Associated Clonal Hematologic Non-Mast Cell Lineage Disease cohort.

Asset / SponsorPhaseRating
Avapritinib
Blueprint Medicines Corporation
Phase 2BB
Bezuclastinib
Cogent Biosciences, Inc.
Phase 2CCC

Same molecule, other indications

Midostaurin is also rated in:

acute myeloid leukemia by FAB classificationActive
B
Indicative · Phase 2
63 / 100
View asset →
acute myeloid leukemiaActive
B
Indicative · Phase 3
62 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Active
B
Indicative · Phase 3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →